Prescient Therapeutics to present CellPryme and OmniCAR data to International Society of Cell and Gene Therapy
The prestigious International Society of Cell and Gene Therapy (ISCT) will showcase two abstracts from Prescient...
The prestigious International Society of Cell and Gene Therapy (ISCT) will showcase two abstracts from Prescient...
Prescient Therapeutics Ltd (ASX:PTX) has strengthened its board through the appointment of experienced pharma executive Dr...
Clinical-stage oncology company Prescient Therapeutics Ltd (ASX:PTX) has fielded more promising results from its PTX-100 T Cell...
Prescient Therapeutics Ltd (ASX:PTX) CEO Steven Yatomi-Clarke tells Proactive the company has been granted additional Orphan Drug Designation...
Prescient Therapeutics Ltd (ASX:PTX) is trading higher on being granted additional Orphan Drug Designation for PTX-100 for...
Since the last trial update, a patient with relapsed peripheral T cell lymphoma reported a...
Prescient Therapeutics Ltd (ASX:PTX) CEO and managing director Steven Yatomi-Clarke chats with Andrew Scott from Proactive about the...
Prescient Therapeutics Ltd (ASX:PTX) continues to demonstrate a favourable safety profile with its PTX-100 Phase 1b expansion...
“It is very exciting to see PTX-100 show clinical activity in a patient population that...
Prescient Therapeutics Ltd (ASX:PTX) has brought in another A$2.5 million in a top-up placement to cater...

This investor centre was built by Reach Markets
©2026 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.